Appointment of Secretarial Auditor and Reappointment of Cost Auditor
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Sandu Pharmaceuticals approved audited financial results (standalone and consolidated) for Q4 and FY ended March 31, 2025, along with a final dividend of Rs. 0.80 per share (8% on face value of Rs. 10), subject to shareholder approval. The company has no subsidiary anymore after selling its entire stake in Sandu Phytoceuticals Private Limited on August 10, 2024, which has since been struck off from MCA records. M/s Swapnil J Dixit and Associates was appointed as the new Secretarial Auditor for a five-year term (FY26–FY30), replacing the prior auditor whose term ended on March 31, 2025. M/s Shekhar Joshi & Co was reappointed as Cost Auditor for FY26. The board also approved reclassifying Akshath Finvest and Properties Pvt Ltd (holding 5.12% or 4,94,182 shares) from the Promoter category to the Public category.
Routine governance updates with a modest dividend and no negative surprises; the promoter-to-public reclassification reduces the formal promoter shareholding, which is generally a neutral-to-slightly-negative governance signal but here is a small 5.12% holder. No impact on business operations expected.